MIKADO: A multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine

HIV Medicine

Volumn 2, Issue 1, 2001, Pages 20-26

  Katlama, C ^a   Pellegrin, J L ^b   Lacoste, D ^c   Aquilina, C ^d   Raffi, F ^e   Pialoux, G ^f   Vittecoq, D ^g   Raguin, G ^h   Lantz, O ⁱ   Mouroux, M ^a   Calvez, V ^a   Trylesinski, A ^j   Montestruc, F ^j   Dohin, E ^j   Goehrs, Jm ^j   Delfraissy, Jf ⁱ  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d Serv Univ Psychiat l'Enfant l'A   (France)

^e HÔTEL DIEU   (France)

^f INSTITUT PASTEUR   (France)

^g HÔPITAL PAUL BROUSSE   (France)

^h GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

ⁱ BICÊTRE HOSPITAL   (France)

^j Produits Roche   (France)

more..

Author keywords

Antiretroviral therapy; HIV 1; Saquinavir SGC; Stavudine; Zalcitabine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHOLESTEROL; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZALCITABINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; MUTATION; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CAPSULES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FRANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PILOT PROJECTS; RNA, VIRAL; SAQUINAVIR; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD; ZALCITABINE;

EID: 0035194335     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.00046.x     Document Type: Article

References (29)

1. Immunologic and viral mechanisms implicated in HIV infection: The impact of treatment
2. New French Guidelines for Antiretroviral Treatment
3. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
4. Antiretroviral therapy in adults, update recommendations of the International AIDS society - USA panel
5. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
6. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients
7. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)
8. Quadruple therapy with saquinavir-soft gelatin capsules (SQV-SGC) plus nelfinavir (NFV) versus triple therapy with either SQV-SGC, or NFV, in patients with antiretroviral experience or high baseline viral load
9. Lamivudine or stavudine in two- or three-drug combination against human immunodeficiency virus type 1 replication in vitro
10. Activity of soft gelatin capsule formulation of saquinavir in combination with two nucleosides in treatment-naive HIV-1-seropositive persons
11. Fortovase (SQV) SGC BID, regimens in combination with 2 nucleosides or nelfinavir (NFV) plus 1 nucleoside in HIV-1 infected patients
12. Amprenavir (141W94, APV USAN approved)/ 3TC/ZDV is superior to 3TC/ZDV in HIV-1 infected antiretroviral naïve subjects
13. Ziagen/Combivir is equivalent to indinavir/Combivir in antiretroviral therapy (ART) naïve adults at 24 weeks (CAN3005)
14. A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients
15. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229
16. Mechanisms of virological failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
17. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
18. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
19. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population
20. 3
21. Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European Expanded Access programme
22. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex
23. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey
24. Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients
25. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients
26. Incidence of neuropathy in HIV-infected patients taking monotherapy vs. combination therapy with didanosine, stavudine, and hydroxyurea
27. Saquinavir soft-gel capsule formulation: A review of its use in patients with HIV infection
28. The development of resistance of HIV-1 to zalcitabine